Nov 28, 2023
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
Additional Formats
Nov 09, 2023
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Additional Formats
Nov 04, 2023
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
Additional Formats
Nov 03, 2023
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Additional Formats
Oct 18, 2023
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
Additional Formats
Sep 27, 2023
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
Additional Formats
Sep 26, 2023
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
Additional Formats
Sep 06, 2023
Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Additional Formats
Aug 10, 2023
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Additional Formats
Aug 02, 2023
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
Additional Formats
Displaying 1 - 10 of 20